GlassScriptPhysician profile
Jodi C Mcclain
NPI 1467858431
$1,586.26
in general payments reported to CMS, 2019-2025
18 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $314 · 2022: $381 · 2023: $161 · 2024: $279 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.08 |
| Education | $124.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $592.26 | 2021-2025 | Enhertu, Lynparza, Datroway |
| Seagen INC. | $206.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $102.27 | 2024-2025 | |
| Incyte Corporation | $99.00 | 2023 | |
| Exelixis INC. | $90.58 | 2022-2024 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $89.66 | 2021 | |
| Merck Sharp & Dohme LLC | $65.48 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $65.07 | 2024-2025 | Rybrevant |
| Pfizer INC. | $58.90 | 2022-2025 | |
| Astellas Pharma US INC | $39.95 | 2022 | |
| Abbvie INC. | $34.13 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.72 | 2023 | Reblozyl |
| Helsinn Therapeutics (U.S.), INC. | $27.11 | 2022 | |
| Tempus Ai, INC | $21.50 | 2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $19.85 | 2024 | Orgovyx |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $19.38 | 2023 | Krazati |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Rigel Pharmaceuticals, INC. | $9.90 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.